Paul Dent

29.1k total citations · 4 hit papers
388 papers, 23.1k citations indexed

About

Paul Dent is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Paul Dent has authored 388 papers receiving a total of 23.1k indexed citations (citations by other indexed papers that have themselves been cited), including 299 papers in Molecular Biology, 122 papers in Oncology and 69 papers in Cell Biology. Recurrent topics in Paul Dent's work include Cell death mechanisms and regulation (75 papers), Histone Deacetylase Inhibitors Research (62 papers) and Autophagy in Disease and Therapy (55 papers). Paul Dent is often cited by papers focused on Cell death mechanisms and regulation (75 papers), Histone Deacetylase Inhibitors Research (62 papers) and Autophagy in Disease and Therapy (55 papers). Paul Dent collaborates with scholars based in United States, Russia and Canada. Paul Dent's co-authors include Steven Grant, Mohamed Rahmani, Paul B. Fisher, Thomas W. Sturgill, Adly Yacoub, Yun Dai, Kristoffer Valerie, Laurence Booth, Rupert Schmidt‐Ullrich and Michael P. Hagan and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Paul Dent

387 papers receiving 22.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of the EGF-Activated MAP Kinase Signaling Pathway by Adenosine 3′,5′-Monophosphate

1993 824 citations Paul Dent et al. profile →
Activation of Mitogen-Activated Protein Kinase Kinase by v-Raf in NIH 3T3 Cells and in Vitro

1992 603 citations Paul Dent et al. profile →
Bile acids as regulatory molecules

2009 562 citations Paul Dent et al. profile →
MAPK pathways in radiation responses

2003 523 citations Paul Dent, Adly Yacoub et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Dent United States	81	15.6k	7.0k	3.0k	2.8k	2.4k	388	23.1k
Steven Grant United States	79	16.7k 1.1×	6.3k 0.9×	2.1k 0.7×	2.0k 0.7×	2.3k 1.0×	451	23.2k
David J. McConkey United States	95	15.9k 1.0×	7.2k 1.0×	2.2k 0.8×	2.1k 0.8×	4.2k 1.8×	385	27.3k
James A. McCubrey United States	79	16.1k 1.0×	6.8k 1.0×	1.6k 0.5×	1.6k 0.6×	3.9k 1.6×	421	24.9k
John L. Cleveland United States	78	14.8k 0.9×	6.8k 1.0×	3.3k 1.1×	1.8k 0.7×	3.3k 1.4×	224	22.7k
Nissim Hay United States	75	20.2k 1.3×	4.9k 0.7×	2.2k 0.7×	2.1k 0.7×	6.5k 2.7×	160	27.9k
Eric W.‐F. Lam United Kingdom	87	15.3k 1.0×	5.4k 0.8×	1.5k 0.5×	1.7k 0.6×	4.0k 1.7×	298	23.1k
Brett P. Monia United States	77	13.9k 0.9×	3.3k 0.5×	3.0k 1.0×	1.4k 0.5×	3.4k 1.4×	274	21.8k
Takashi Tsuruo Japan	89	16.6k 1.1×	12.4k 1.8×	1.3k 0.4×	2.1k 0.7×	2.8k 1.2×	446	27.7k
David C.S. Huang Australia	82	20.4k 1.3×	6.2k 0.9×	2.9k 1.0×	2.0k 0.7×	2.5k 1.1×	236	28.2k
Robert T. Abraham United States	88	20.2k 1.3×	7.5k 1.1×	1.9k 0.6×	3.2k 1.1×	4.4k 1.9×	215	29.0k

Countries citing papers authored by Paul Dent

Since Specialization

Citations

This map shows the geographic impact of Paul Dent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Dent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Dent more than expected).

Fields of papers citing papers by Paul Dent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Dent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Dent. The network helps show where Paul Dent may publish in the future.

Co-authorship network of co-authors of Paul Dent

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Dent. A scholar is included among the top collaborators of Paul Dent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Dent. Paul Dent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Booth, Laurence, Jane L. Roberts, Cameron West, & Paul Dent. (2024). GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells. Oncotarget. 15(1). 159–174. 2 indexed citations

Booth, Laurence, Jane L. Roberts, Heath Ecroyd, et al.. (2016). AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. Journal of Cellular Physiology. 231(10). 2286–2302. 33 indexed citations

Chen, Shuang, Yun Dai, Li Wang, et al.. (2012). CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies. Cancer Research. 72(16). 4225–4237. 46 indexed citations

Das, Swadesh K., Sujit K. Bhutia, Belal Azab, et al.. (2012). MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma. Cancer Research. 73(2). 844–854. 79 indexed citations

Park, Margaret A., Adly Yacoub, Hossein A. Hamed, et al.. (2011). Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells. Cancer Research. 71(14). 4955–4967. 97 indexed citations

Dash, Rupesh, Belal Azab, Bridget A. Quinn, et al.. (2011). Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda -7/IL-24–mediated toxicity. Proceedings of the National Academy of Sciences. 108(21). 8785–8790. 101 indexed citations

Park, Margaret A., Clint Mitchell, Guo Zhang, et al.. (2010). Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+- De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway. Cancer Research. 70(15). 6313–6324. 86 indexed citations

Park, Margaret A., Roland Reinehr, Dieter Häussinger, et al.. (2010). Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells. Molecular Cancer Therapeutics. 9(8). 2220–2231. 74 indexed citations

Bhutia, Sujit K., Rupesh Dash, Swadesh K. Das, et al.. (2010). Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/Interleukin-24. Cancer Research. 70(9). 3667–3676. 102 indexed citations

10.

Yacoub, Adly, Hossein A. Hamed, Jeremy C. Allegood, et al.. (2010). PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in mda -7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells. Cancer Research. 70(3). 1120–1129. 89 indexed citations

11.

Walker, Teneille, Clint Mitchell, Margaret A. Park, et al.. (2010). 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species. Molecular Cancer Therapeutics. 9(5). 1378–1395. 16 indexed citations

12.

Kapitonov, Dmitri, Jeremy C. Allegood, Clint Mitchell, et al.. (2009). Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts. Cancer Research. 69(17). 6915–6923. 154 indexed citations

13.

Park, Margaret A., Teneille Walker, Aditi Pandya Martin, et al.. (2009). MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism. Molecular Cancer Therapeutics. 8(5). 1280–1291. 40 indexed citations

14.

Zhang, Guo, Margaret A. Park, Clint Mitchell, et al.. (2008). Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation. Clinical Cancer Research. 14(17). 5385–5399. 101 indexed citations

15.

Park, Margaret A., Guo Zhang, Clint Mitchell, et al.. (2008). Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Molecular Cancer Therapeutics. 7(9). 2633–2648. 41 indexed citations

16.

Dai, Yun, et al.. (2008). Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research. 14(2). 549–558. 68 indexed citations

17.

Golding, Sarah E., Elizabeth Rosenberg, Steven J. Neill, et al.. (2007). Extracellular Signal-Related Kinase Positively Regulates Ataxia Telangiectasia Mutated, Homologous Recombination Repair, and the DNA Damage Response. Cancer Research. 67(3). 1046–1053. 145 indexed citations

18.

Sankala, Heidi, Nitai C. Hait, Steven W. Paugh, et al.. (2007). Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin. Cancer Research. 67(21). 10466–10474. 132 indexed citations

19.

Awasthi, Sanjay, Sharad S. Singhal, Sushma Yadav, et al.. (2005). RLIP76 Is a Major Determinant of Radiation Sensitivity. Cancer Research. 65(14). 6022–6028. 79 indexed citations

20.

Smith, Roger, Albert J. Baukal, Paul Dent, & Kevin Catt. (1999). Raf-1 Kinase Activation by Angiotensin II in Adrenal Glomerulosa Cells: Roles of Gi, Phosphatidylinositol 3-Kinase, and Ca2+ Influx. Endocrinology. 140(3). 1385–1391. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact